Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00622544 · ClinicalTrials.gov registry record
A Prospective Study of Microalbuminuria in Untreated Boys With Alport Syndrome
A clinical trial of Kidney Disease and Alport Syndrome, sponsored by University of Minnesota.
- Completed
- Registry status
- 44
- Enrollment target
- 1
- Study location
NCT00622544: Completed study of Kidney Disease and Alport Syndrome, sponsored by University of Minnesota.
NCT00622544 is a study of Kidney Disease and Alport Syndrome that has completed, run by University of Minnesota. The registered enrollment target is 44 participants, below the 2,938-participant average among 23 other Kidney Disease trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00622544, a study of Kidney Disease and Alport Syndrome, has completed, sponsored by University of Minnesota.
- COMPLETED
- Registry status
- 44 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of the Microalbuminuria in Untreated Boys with Alport Syndrome study is to gather information about critical clinical time points such as when patients with small amounts of protein (microalbuminuria) in their urine progress to larger amounts (overt proteinuria). Large amounts of protein in the urine is often an early sign of kidney disease. Information needs to be collected in boys who are not taking medications known as angiotensin converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) in order to obtain accurate data about the length of time between the onset of microalbuminuria and the start of overt proteinuria. This new information will give physicians a better understanding of how to treat patients with Alport syndrome. The information we gather by conducting this study will aid in planning future clinical trials because the identification of time points in disease progression, such as microalbuminuria and overt proteinuria, could reduce the time necessary to show a clinical benefit of a new treatment option. The study has been approved by the University of Minnesota's Institutional Review Board.
Primary Outcome
number of subjects developing microalbuminuria during study period
Conditions Studied
Study Locations (1)
Minnesota
- University of Minnesota - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2007-07 |
| Est. Completion | 2012-07 |
What the finished NCT00622544 record still lists
NCT00622544 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 44 participants, a relatively small participant target, below the 2,938-participant average among 23 other Kidney Disease trials with a reported enrollment target (99% lower).
The record links to 2 conditions, with Kidney Disease appearing as the primary indexed condition, and to 0 interventions.
NCT00622544 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT00622544 about?
NCT00622544 is a clinical study titled "A Prospective Study of Microalbuminuria in Untreated Boys With Alport Syndrome". The goal of the Microalbuminuria in Untreated Boys with Alport Syndrome study is to gather information about critical clinical time points such as when patients with small amounts of protein (microalbuminuria) in their urine progress to larger amounts (overt proteinuria). Large amounts of protein in...
What is the current status of trial NCT00622544?
This trial is currently completed. The enrollment target is 44 participants. The study started on 2007-07. Estimated completion is 2012-07.
What conditions does trial NCT00622544 study?
This clinical trial studies the following conditions: Kidney Disease, Alport Syndrome.
Who is sponsoring clinical trial NCT00622544?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00622544 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Kidney Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00622544's enrollment target sits among peer trials
44 16th of 23 higher than 8 of 23 other Kidney Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Kidney Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Rutgers University Study of the Genetics of Kidney Disease
RECRUITING
-
Cardiovascular Kidney and Metabolic Health Assessment and Patient Empowerment
RECRUITING · NA
-
A Study of Mezagitamab in Adults With Primary IgA Nephropathy Kidney Condition
RECRUITING · Phase 3
-
Nicotinamide Riboside Supplementation for Treating Arterial Stiffness and Elevated Systolic Blood Pressure in Patients With Moderate to Severe CKD
RECRUITING · Phase 2
-
Inspire HER: Inspiring the Heart and Emotions for Radical Health
RECRUITING · NA
-
Outcomes of Physiologic Insulin Resensitization (PIR) in Patients With Chronic Kidney Disease and Type 2 Diabetes Mellitus
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02323945 · 44 participants · NA
Effects of Breathing Mild Bouts of Low Oxygen on Limb Mobility After Spinal Injury
- NCT03093909 · 44 participants · Phase 1
Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases
- NCT03104491 · 44 participants · Phase 1
Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia
- NCT03781765 · 44 participants · Phase 4
Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia